Honokiol In Combination With A Low Dose Oxaliplatin Can Induced Apoptosis Of The Human Lung Adenocarcinoma A549 Cells

Honokiol is a kind of compounds with hydroxypropyl joint hydroquinone.It is separated from a kind of traditional Chinese medicine Magnolia, which have biological activity and a variety of pharmacological effects. Among of effects, the most attention is its anti-tumor effect. Mainly it manifests in the following areas:induced apoptosis of tumor cells and promote tumor cell differentiation, inhibit tumor cell proliferation, inhibit tumor cell metastasis, inhibit angiogenesis, the role reversal of multi-drug resistance.Oxaliplatin is considered of the third-generation platinum-type antineoplastic agents. Currently oxaliplatin is widely used. In vitro, the effect of oxaliplatin is better than cisplatin. However, as chemotherapy drugs, oxaliplatin are peripheral neuropathy and other serious side effects.In this study, different concentrations of honokiol, low-dose oxaliplatin, or both combined effects on the human lung adenocarcinoma A549 cells.After the A549 cell is cultured for 48 hours incorporation of these drugs, MTT is employed to investigate proliferation of drugs on human pulmonary gland carcinoma A549 cells. Flow cytometry is used to investigate the cell apoptosis.The results showed that Compared to honokiol or oxaliplatin alone, significant improvements in cell apoptosis and growth inhibition indexes were observed in the combined treatment. These findings indicate that parthenolide could markedly enhance sensitivity of A549 cells to low dose oxaliplatin by inducing apoptosis in vitro experiments. honokiol in combination with a low dose oxaliplatin may be a beneficial chemotherapeutic strategy for patients who cannot tolerate the severe side-effects of the drug at therapeutic concentrations.